Unique angiogenic and vasculogenic properties of renal cell carcinoma in a xenograft model of bone metastasis are associated with high levels of vegf-a and decreased ang-1 expression

Journal of Orthopaedic Research

Volumn 30, Issue 2, 2012, Pages 325-333

  Xie, Chao ^a,b   Schwarz, Edward M ^a,b   Sampson, Erik R ^a,b   Dhillon, Robinder S ^a   Li, Dan ^a,b   O'Keefe, Regis J ^a,b   Tyler, Wakenda ^a,b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

bone metastasis; renal cell carcinoma (RCC); vasculogenesis; xenograft

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; FIREFLY LUCIFERASE; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANG 1 GENE; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; BONE METASTASIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER MODEL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HISTOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CARCINOMA; MEASUREMENT; MOUSE; NONHUMAN; NUDE MOUSE; OSTEOLYSIS; PRIORITY JOURNAL; TUMOR XENOGRAFT; VEGF A GENE;

ANGIOPOIETIN-1; ANIMALS; BONE NEOPLASMS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; HUMANS; KIDNEY NEOPLASMS; MICE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 83855162887     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.21500     Document Type: Article

References (44)

1. Howlader N, Noone AM, Krapcho M,. National Cancer. NCI Surveillance, Epidemiology and End Results (SEER) Program for statistics on Cancer. 2009.
2. Schoffski P, Dumez H, Clement P, et al. 2006. Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Ann Oncol 17 (8): 1185-1196. (Pubitemid 44288208)
3. Ng CS, Wood CG, Silverman PM, et al. 2008. Renal cell carcinoma: diagnosis, staging, and surveillance. Am J Roentgenol 191 (4): 1220-1232.
4. Zagoria RJ, Bechtold RE,. 1997. The role of imaging in staging renal adenocarcinoma. Semin Ultrasound CT MR 18 (2): 91-99. (Pubitemid 27209746)
5. Kim WY, Kaelin WG,. 2004. Role of VHL gene mutation in human cancer. J Clin Oncol 22 (24): 4991-5004. (Pubitemid 46646218)
6. Patel PH, Chadalavada RS, Chaganti RS, et al. 2006. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res 12 (24): 7215-7220. (Pubitemid 46095391)
7. Mellado B, Gascon P,. 2006. Molecular biology of renal cell carcinoma. Clin Transl Oncol 8 (10): 706-710.
8. Nemeth JA, Harb JF, Barroso U, et al. 1999. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res 59 (8): 1987-1993. (Pubitemid 29186176)
9. McLemore TL, Eggleston JC, Shoemaker RH, et al. 1988. Comparison of intrapulmonary, percutaneous intrathoracic, and subcutaneous models for the propagation of human pulmonary and nonpulmonary cancer cell lines in athymic nude mice. Cancer Res 48 (10): 2880-2886.
10. Yoneda T, Sasaki A, Dunstan C, et al. 1997. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 99 (10): 2509-2517. (Pubitemid 27227730)
11. Nakai M, Mundy GR, Williams PJ, et al. 1992. A synthetic antagonist to laminin inhibits the formation of osteolytic metastases by human melanoma cells in nude mice. Cancer Res 52 (19): 5395-5399.
12. Feeley BT, Krenek L, Liu N, et al. 2006. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Bone 38 (2): 154-166. (Pubitemid 43165781)
13. He X, Wang J, Messing EM, et al. 2011. Regulation of receptor for activated C kinase 1 protein by the von Hippel-Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness. Oncogene 30 (5): 535-547.
14. Shi YE, Ni J, Xiao G, et al. 1997. Antitumor activity of the novel human breast cancer growth inhibitor, mammary-derived growth inhibitor-related gene, MRG. Cancer Res 57 (15): 3084-3091. (Pubitemid 27351715)
15. Ionescu AM, Drissi H, Schwarz EM, et al. 2004. CREB cooperates with BMP-stimulated Smad signaling to enhance transcription of the Smad6 promoter. J Cell Physiol 198 (3): 428-440. (Pubitemid 38235038)
16. Zhang X, Xie C, Lin AS, et al. 2005. Periosteal progenitor cell fate in segmental cortical bone graft transplantations: implications for functional tissue engineering. J Bone Miner Res 20 (12): 2124-2137. (Pubitemid 41698776)
17. Na X, Wu G, Ryan CK, et al. 2003. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J Urol 170 (2 Pt 1): 588-592. (Pubitemid 36870265)
18. Ahmad SA, Liu W, Jung YD, et al. 2001. The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. Cancer Res 61 (4): 1255-1259. (Pubitemid 34292536)
19. Stoeltzing O, Ahmad SA, Lin W, et al. 2002. Angiopoietin-1 inhibits tumour growth and ascites formation in a murine model of peritoneal carcinomatosis. Br J Cancer 87 (10): 1182-1187. (Pubitemid 35422722)
20. Stoeltzing O, Ahmad SA, Lin W, et al. 2003. Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Res 63 (12): 3370-3377. (Pubitemid 36735897)
21. Tian S, Hayes AJ, Metheny-Barlow LJ, et al. 2002. Stabilization of breast cancer xenograft tumour neovasculature by angiopoietin-1. Br J Cancer 86 (4): 645-651. (Pubitemid 34185105)
22. Lin PP, Mirza AN, Lewis VO, et al. 2007. Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am 89 (8): 1794-1801. (Pubitemid 47229888)
23. Yossepowitch O, Bianco FJ, Jr, Eggener SE, et al. 2007. The natural history of noncastrate metastatic prostate cancer after radical prostatectomy. Eur Urol 51 (4): 940-947, discussion 947-948.
24. Oya M,. 2009. Renal cell carcinoma: biological features and rationale for molecular-targeted therapy. Keio J Med 58 (1): 1-11.
25. Kamura T, Koepp DM, Conrad MN, et al. 1999. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 284 (5414): 657-661. (Pubitemid 29289593)
26. Kamura T, Sato S, Iwai K, et al. 2000. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 97 (19): 10430-10435.
27. Ravaud A,. 2011. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist 16 (Suppl 2): 32-44.
28. Haigh JJ, Gerber HP, Ferrara N, et al. 2000. Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state. Development 127 (7): 1445-1453. (Pubitemid 30232595)
29. Thurston G,. 2002. Complementary actions of VEGF and angiopoietin-1 on blood vessel growth and leakage. J Anat 200 (6): 575-580. (Pubitemid 34823049)
30. Abbott BD, Buckalew AR,. 2000. Placental defects in ARNT-knockout conceptus correlate with localized decreases in VEGF-R2, Ang-1, and Tie-2. Dev Dyn 219 (4): 526-538.
31. Jain RK, Munn LL,. 2000. Leaky vessels? Call Ang1. Nat Med 6 (2): 131-132.
32. Detmar M, Brown LF, Schon MP, et al. 1998. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 111 (1): 1-6. (Pubitemid 28309201)
33. Suri C, McClain J, Thurston G, et al. 1998. Increased vascularization in mice overexpressing angiopoietin-1. Science 282 (5388): 468-471. (Pubitemid 28483672)
34. Thurston G, Suri C, Smith K, et al. 1999. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286 (5449): 2511-2514.
35. Herbst RS, Hong D, Chap L, et al. 2009. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 27 (21): 3557-3565.
36. Hansbury MJ, Nicosia RF, Zhu WH, et al. 2001. Production and characterization of a Tie2 agonist monoclonal antibody. Angiogenesis 4 (1): 29-36. (Pubitemid 34032034)
37. Shim WS, Teh M, Mack PO, et al. 2001. Inhibition of angiopoietin-1 expression in tumor cells by an antisense RNA approach inhibited xenograft tumor growth in immunodeficient mice. Int J Cancer 94 (1): 6-15. (Pubitemid 32801746)
38. Chae JK, Kim I, Lim ST, et al. 2000. Coadministration of angiopoietin-1 and vascular endothelial growth factor enhances collateral vascularization. Arterioscler Thromb Vasc Biol 20 (12): 2573-2578.
39. Thurston G, Rudge JS, Ioffe E, et al. 2000. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 6 (4): 460-463. (Pubitemid 30208166)
40. Hayes AJ, Huang WQ, Yu J, et al. 2000. Expression and function of angiopoietin-1 in breast cancer. Br J Cancer 83 (9): 1154-1160.
41. Ahmad SA, Liu W, Jung YD, et al. 2001. Differential expression of angiopoietin-1 and angiopoietin-2 in colon carcinoma. A possible mechanism for the initiation of angiogenesis. Cancer 92 (5): 1138-1143. (Pubitemid 32861662)
42. Udani V, Santarelli J, Yung Y, et al. 2005. Differential expression of angiopoietin-1 and angiopoietin-2 may enhance recruitment of bone-marrow-derived endothelial precursor cells into brain tumors. Neurol Res 27 (8): 801-806. (Pubitemid 41790264)
43. Virk MS, Lieberman JR,. 2007. Tumor metastasis to bone. Arthritis Res Ther 9 (Suppl 1): S5.
44. Kominsky SL, Doucet M, Thorpe M, et al. 2008. MMP-13 is over-expressed in renal cell carcinoma bone metastasis and is induced by TGF-beta1. Clin Exp Metastasis 25 (8): 865-870.